Clinical trial
Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast…
NCT00482755 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00482755 |
|---|---|
| Title | Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery |
| Official title | A Feasibility Study of Pre-Operative Sunitinib (SU11248) With Multiple Pharmacodynamic Endpoints in Patients With T1c-T3 Operable Carcinoma of the Breast |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug, Other, Procedure |
| Interventions | sunitinib malate, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, needle biopsy, neoadjuvant therapy |
| Enrollment | 4 |
| Start date | Apr 8, 2009 |
| Primary completion | Mar 15, 2010 |
| Completion | Jan 18, 2011 |
| First posted | Jun 5, 2007 |
| Last update posted | Feb 12, 2024 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: